

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims

Claims 1-48 (Cancelled).

49. (New) A method for determining the prognosis for an AML affected subject, said method comprising the steps of:

a) determining, by means of assays conducted on a substrate, a level of expression for each of at least five cluster-specific genes selected from one of the clusters #9, #12 and #13, corresponding to AML classes of inv(16), t(15;17) or t(8;21) respectively;

b) establishing the similarity of the level of expression of said at least five cluster-specific genes in said subject to the level of expression of said genes in patients selected from an established AML class selected from the group consisting of inv(16), t(15;17) and t(8;21); and

c) assigning to said subject a prognosis based on the similarity of level of expression of step e) corresponding to the established AML class.

50. (New) The method according to claim 49 wherein in step c) the substrate is an Affymetrix GeneChip.

51. (New) The method according to claim 50 wherein in step a) the level of expression of at least eight cluster-specific genes is determined.

52. (New) Method according to claim 50 wherein the at least five cluster-specific genes from cluster #9 are MYH11, CLIPR-59, ST18, NRP1 and CLECSF13.

53. (New) Method according to claim 50 wherein the at least five cluster-specific genes from cluster #12 are HGF, FGF13, MEG3, GABRE and MST1.

Application No. 10/590,385

Paper Dated 13 December 2010

In Reply to Office Action of August 12, 2010

Attorney Docket No. 3691-062550

54. (New) Method according to claim 50 wherein the at least five cluster-specific genes from cluster #13 are CBFA2T1, ROBO1, CACNA2D2, POU4F1 and IL5RA.